1. Scrip

Hikma 'sixth largest US generics firm' following Roxane buy from Boehringer

 
• By Sukaina Virji

Hot on the heels of Teva's acquisition of Allergan's generics business, Hikma Pharmaceuticals has agreed to buy US generics firm Roxane Laboratories from Boehringer Ingelheim in a deal worth around $2.65bn, making Hikma "the sixth largest generics company" by revenue in the US. "The US generics market is currently a very attractive place to be," Hikma's CEO Said Darwazah told Scrip. "If you want to grow fast, there is no other market that can provide you with this kind of opportunity."

Hot on the heels of Teva's acquisition of Allergan's generics business, Hikma Pharmaceuticals has agreed to buy US generics firm Roxane Laboratories from Boehringer Ingelheim in a deal worth around $2.65bn, making Hikma "the sixth largest generics company" by revenue in the US. "The US generics market is currently a very attractive place to be," Hikma's CEO Said Darwazah told Scrip. "If you want to grow fast, there is no other market that can provide you with this kind of opportunity."

Under the agreement, London-listed Hikma will pay $1.18bn in cash and issue 40 million new Hikma shares to Boehringer. This...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Scrip

Four Chinese Firms Snag Global First-In-Class Approvals In China

 
• By Dexter Jie Yan

Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 
• By Alaric DeArment

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Merck & Co. Remains In The BD Game After Verona Takeout

 
• By Jessica Merrill

CEO Rob Davis said the company is in pursuit of more deals as it looks to close the revenue gap looming from the loss of Keytruda in 2028.